Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000–500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Nyaku, Amesika N, Zheng, Lu, Gulick, Roy M, Olefsky, Maxine, Berzins, Baiba, Wallis, Carole L, Godfrey, Catherine, Sax, Paul E, Acosta, Edward P, Haas, David W, Smith, Kimberly Y, Sha, Beverly E, Van Dam, Cornelius N, Taiwo, Babafemi O
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477973/
https://ncbi.nlm.nih.gov/pubmed/30668695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky564
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados